This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Davangere P. Devanand, MD; Harold A. Sackeim, PhD; Richard P. Brown, MD; Richard Mayeux, MD

Arch Neurol. 1989;46(8):854-857.

Abstract
• Nine outpatients meeting research criteria for probable Alzheimer's disease who had psychosis or behavioral disturbance participated in a single-blind, placebo-controlled pilot study. Oral haloperidol in doses of 1 to 5 mg daily improved target symptoms, confirmed by doubleblind ratings of videotaped interviews. Patients could not be maintained on more than 4 mg of haloperidol daily due to the severity of extrapyramidal side effects. Modified Mini-Mental State scores worsened while taking haloperidol, with only partial recovery in the final 4-week placebo phase. Severe extrapyramidal side effects and decline in cognitive function may compromise the efficacy of commonly used doses of neuroleptic drugs in patients with Alzheimer's disease.

Author Affiliations
From the Memory Disorders Clinic, Departments of Psychiatry (Drs Devanand, Sackeim, and Brown) and Neurology (Dr Mayeux), College of Physicians and Surgeons, Columbia University and the Department of Biological Psychiatry, New York State Psychiatric Institute (Drs Devanand, Sackeim, Brown, and Mayeux), New York, NY.

Footnotes
Accepted for publication January 10, 1989.

Address reprint requests to Department of Biological Psychiatry, New York State Psychiatric Institute, Box 72, 722 W 168th St, New York, NY 10032 (Dr Devanand).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults
Brooks and Hoblyn
J Geriatr Psychiatry Neurol 2007;20:199-214.
ABSTRACT  

Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: A 24-month follow-up of 68 patients
Moretti et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2003;18:205-214.
ABSTRACT  

Patterns of Change in the Treatment of Psychiatric Symptoms in Patients With Probable Alzheimer's Disease From 1983 to 2000
Lopez et al.
J. Neuropsychiatry Clin. Neurosi. 2003;15:67-73.
ABSTRACT | FULL TEXT  

Efficacy of Metrifonate in Improving the Psychiatric and Behavioral Disturbances of Patients with Alzheimer's Disease
Cummings et al.
J Geriatr Psychiatry Neurol 2001;14:101-108.
ABSTRACT  

Treatment of agitation in AD: A randomized, placebo-controlled clinical trial
Teri et al.
Neurology 2000;55:1271-1278.
ABSTRACT | FULL TEXT  

Olanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care Facilities: A Double-blind, Randomized, Placebo-Controlled Trial
Street et al.
Arch Gen Psychiatry 2000;57:968-976.
ABSTRACT | FULL TEXT  

Psychiatric Medication and Abnormal Behavior as Predictors of Progression in Probable Alzheimer Disease
Lopez et al.
Arch Neurol 1999;56:1266-1272.
ABSTRACT | FULL TEXT  

Pharmacologic Efficacy in Neuropsychiatry: A Review of Placebo-Controlled Treatment Trials
Rummans et al.
J. Neuropsychiatry Clin. Neurosi. 1999;11:176-189.
ABSTRACT | FULL TEXT  

Diagnosis, Management, and Treatment of Alzheimer Disease: A Guide for the Internist
Richards and Hendrie
Arch Intern Med 1999;159:789-798.
ABSTRACT | FULL TEXT  

A Randomized, Placebo-Controlled Dose-Comparison Trial of Haloperidol for Psychosis and Disruptive Behaviors in Alzheimer's Disease
Devanand et al.
Am. J. Psychiatry 1998;155:1512-1520.
ABSTRACT | FULL TEXT  

The Course of Psychopathologic Features in Mild to Moderate Alzheimer Disease
Devanand et al.
Arch Gen Psychiatry 1997;54:257-263.
ABSTRACT  

Biologic Markers and Neurochemical Correlates of Agitation and Psychosis in Dementia
Kirby and Lawlor
J Geriatr Psychiatry Neurol 1995;8:S2-S7.
ABSTRACT  

Neuroleptic Treatment of Agitation and Psychosis in Dementia
Devanand and Levy
J Geriatr Psychiatry Neurol 1995;8:S18-S27.
ABSTRACT  

Early Detection of Neuroleptic-Induced Parkinsonism in Elderly Patients with Dementia
Sweet et al.
J Geriatr Psychiatry Neurol 1994;7:251-253.
ABSTRACT  

Sodium Valproate in the Treatment of Behavioral Disturbance in Dementia
Mellow et al.
J Geriatr Psychiatry Neurol 1993;6:205-209.
ABSTRACT  

Population-Based Norms for the Mini-Mental State Examination by Age and Educational Level
Crum et al.
JAMA 1993;269:2386-2391.
ABSTRACT  

Acute Extrapyramidal Syndromes in Neuroleptic-Treated Elders: A Pilot Study
Ganzini et al.
J Geriatr Psychiatry Neurol 1991;4:222-225.
ABSTRACT